AAPL   383.15 (+0.11%)
MSFT   213.50 (-0.38%)
FB   244.68 (+0.07%)
AMZN   3,199.68 (+0.54%)
NVDA   417.54 (-0.67%)
CGC   17.06 (+6.49%)
BABA   261.03 (-0.21%)
GE   6.69 (+1.52%)
TSLA   1,510.99 (+8.37%)
AMD   55.68 (-2.76%)
ACB   11.87 (+0.85%)
F   6.06 (+3.59%)
GILD   76.41 (+2.28%)
DIS   118.89 (+1.77%)
BAC   23.89 (+4.92%)
NFLX   544.89 (+7.31%)
AAPL   383.15 (+0.11%)
MSFT   213.50 (-0.38%)
FB   244.68 (+0.07%)
AMZN   3,199.68 (+0.54%)
NVDA   417.54 (-0.67%)
CGC   17.06 (+6.49%)
BABA   261.03 (-0.21%)
GE   6.69 (+1.52%)
TSLA   1,510.99 (+8.37%)
AMD   55.68 (-2.76%)
ACB   11.87 (+0.85%)
F   6.06 (+3.59%)
GILD   76.41 (+2.28%)
DIS   118.89 (+1.77%)
BAC   23.89 (+4.92%)
NFLX   544.89 (+7.31%)
AAPL   383.15 (+0.11%)
MSFT   213.50 (-0.38%)
FB   244.68 (+0.07%)
AMZN   3,199.68 (+0.54%)
NVDA   417.54 (-0.67%)
CGC   17.06 (+6.49%)
BABA   261.03 (-0.21%)
GE   6.69 (+1.52%)
TSLA   1,510.99 (+8.37%)
AMD   55.68 (-2.76%)
ACB   11.87 (+0.85%)
F   6.06 (+3.59%)
GILD   76.41 (+2.28%)
DIS   118.89 (+1.77%)
BAC   23.89 (+4.92%)
NFLX   544.89 (+7.31%)
AAPL   383.15 (+0.11%)
MSFT   213.50 (-0.38%)
FB   244.68 (+0.07%)
AMZN   3,199.68 (+0.54%)
NVDA   417.54 (-0.67%)
CGC   17.06 (+6.49%)
BABA   261.03 (-0.21%)
GE   6.69 (+1.52%)
TSLA   1,510.99 (+8.37%)
AMD   55.68 (-2.76%)
ACB   11.87 (+0.85%)
F   6.06 (+3.59%)
GILD   76.41 (+2.28%)
DIS   118.89 (+1.77%)
BAC   23.89 (+4.92%)
NFLX   544.89 (+7.31%)
Log in

NYSE:LHLaboratory Corp. of America Stock Price, Forecast & News

$172.39
-0.73 (-0.42 %)
(As of 07/10/2020 03:16 PM ET)
Add
Compare
Today's Range
$170.80
Now: $172.39
$174.53
50-Day Range
$157.09
MA: $170.46
$180.64
52-Week Range
$98.02
Now: $172.39
$196.36
Volume292,847 shs
Average Volume833,238 shs
Market Capitalization$16.76 billion
P/E Ratio53.37
Dividend YieldN/A
Beta1.38
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, and medical drug monitoring; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides technology-enabled solutions, including a suite of applications to enable patients, healthcare providers, health systems, accountable care organizations, and insurers with convenient and secure access to LCD's data and services, as well as billing for laboratory services. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, academic institutions, and independent clinical laboratories. Laboratory Corporation of America Holdings has collaborations with the Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, Yale University, and QIAGEN N.V. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Read More
Laboratory Corp. of America logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
CUSIP50540R40
Phone336-229-1127

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.55 billion
Cash Flow$19.22 per share
Book Value$77.93 per share

Profitability

Net Income$823.80 million

Miscellaneous

Employees65,000
Market Cap$16.76 billion
Next Earnings Date7/28/2020 (Confirmed)
OptionableOptionable

Receive LH News and Ratings via Email

Sign-up to receive the latest news and ratings for LH and its competitors with MarketBeat's FREE daily newsletter.

Laboratory Corp. of America (NYSE:LH) Frequently Asked Questions

How has Laboratory Corp. of America's stock been impacted by COVID-19 (Coronavirus)?

Laboratory Corp. of America's stock was trading at $158.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LH shares have increased by 8.4% and is now trading at $172.39. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Laboratory Corp. of America?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Laboratory Corp. of America in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Laboratory Corp. of America.

When is Laboratory Corp. of America's next earnings date?

Laboratory Corp. of America is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Laboratory Corp. of America.

How can I listen to Laboratory Corp. of America's earnings call?

Laboratory Corp. of America will be holding an earnings conference call on Tuesday, July 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Laboratory Corp. of America's earnings last quarter?

Laboratory Corp. of America Holdings (NYSE:LH) posted its quarterly earnings data on Wednesday, April, 29th. The medical research company reported $2.37 earnings per share for the quarter, beating analysts' consensus estimates of $1.95 by $0.42. The medical research company earned $2.82 billion during the quarter, compared to analyst estimates of $2.73 billion. Laboratory Corp. of America had a net margin of 2.77% and a return on equity of 15.03%. The business's revenue was up 1.2% compared to the same quarter last year. During the same period last year, the firm earned $2.62 EPS. View Laboratory Corp. of America's earnings history.

What price target have analysts set for LH?

15 equities research analysts have issued 12-month target prices for Laboratory Corp. of America's stock. Their forecasts range from $170.00 to $244.00. On average, they expect Laboratory Corp. of America's stock price to reach $203.19 in the next year. This suggests a possible upside of 17.9% from the stock's current price. View analysts' price targets for Laboratory Corp. of America.

Has Laboratory Corp. of America been receiving favorable news coverage?

Media coverage about LH stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Laboratory Corp. of America earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Laboratory Corp. of America.

Who are some of Laboratory Corp. of America's key competitors?

What other stocks do shareholders of Laboratory Corp. of America own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Laboratory Corp. of America investors own include Gilead Sciences (GILD), Johnson & Johnson (JNJ), Micron Technology (MU), Amgen (AMGN), Intel (INTC), Pfizer (PFE), AbbVie (ABBV), Cisco Systems (CSCO), NVIDIA (NVDA) and Abbott Laboratories (ABT).

Who are Laboratory Corp. of America's key executives?

Laboratory Corp. of America's management team includes the following people:
  • Mr. David P. King, Chairman, CEO & Pres (Age 63)
  • Mr. Glenn A. Eisenberg, CFO & Exec. VP (Age 58)
  • Mr. F. Samuel Eberts III, Chief Legal Officer, Chief Compliance Officer, Sr. VP & Sec. (Age 59)
  • Mr. John D. Ratliff, Chief Exec. Officer of Covance Drug Devel. (Age 59)
  • Dr. Michelle Abelson, Laboratory Director of Operations

What is Laboratory Corp. of America's stock symbol?

Laboratory Corp. of America trades on the New York Stock Exchange (NYSE) under the ticker symbol "LH."

Who are Laboratory Corp. of America's major shareholders?

Laboratory Corp. of America's stock is owned by many different institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.09%), Forte Capital LLC ADV (0.05%), State of Alaska Department of Revenue (0.03%), American National Bank (0.03%), Jacobs & Co. CA (0.03%) and Webster Bank N. A. (0.02%). Company insiders that own Laboratory Corp. of America stock include David P King, Der Vaart Sandra D Van, Glenn A Eisenberg, Jean-Luc Belingard, Judith C Seltz, Kerrii B Anderson, Lance Berberian, Lisa J Uthgenannt, Mark S Schroeder, Peter J Wilkinson, R Sanders Williams and Robert E Mittelstaedt Jr. View institutional ownership trends for Laboratory Corp. of America.

Which major investors are selling Laboratory Corp. of America stock?

LH stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, American National Bank, DNB Asset Management AS, Envestnet Asset Management Inc., Ipswich Investment Management Co. Inc., Private Trust Co. NA, and Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have sold Laboratory Corp. of America company stock in the last year include David P King, Der Vaart Sandra D Van, Jean-Luc Belingard, Kerrii B Anderson, Lance Berberian, Lisa J Uthgenannt, Mark S Schroeder, Peter J Wilkinson, and R Sanders Williams. View insider buying and selling activity for Laboratory Corp. of America.

Which major investors are buying Laboratory Corp. of America stock?

LH stock was acquired by a variety of institutional investors in the last quarter, including Forte Capital LLC ADV, Cypress Capital Group, Carnegie Capital Asset Management LLC, Fulton Bank N. A., Pure Financial Advisors Inc., Jacobs & Co. CA, Webster Bank N. A., and Richard P Slaughter Associates Inc. View insider buying and selling activity for Laboratory Corp. of America.

How do I buy shares of Laboratory Corp. of America?

Shares of LH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Laboratory Corp. of America's stock price today?

One share of LH stock can currently be purchased for approximately $172.39.

How big of a company is Laboratory Corp. of America?

Laboratory Corp. of America has a market capitalization of $16.76 billion and generates $11.55 billion in revenue each year. The medical research company earns $823.80 million in net income (profit) each year or $11.32 on an earnings per share basis. Laboratory Corp. of America employs 65,000 workers across the globe.

What is Laboratory Corp. of America's official website?

The official website for Laboratory Corp. of America is www.labcorp.com.

How can I contact Laboratory Corp. of America?

Laboratory Corp. of America's mailing address is 358 South Main Street, BURLINGTON NC, 27215. The medical research company can be reached via phone at 336-229-1127 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.